FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
nours per respon-	se 0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)										1	44 05			
Name and Address of Reporting Person * Avgerinos George				1	2. Issuer Name and Ticker or Trading Symbol Fortress Biotech, Inc. [FBIO]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR				′ .	3. Date of Earliest Transaction (Month/Day/Year) 08/31/2015							X Officer (give title below) Other (specify below) SVP, Biologics Operations				
(Street) NEW YORK, NY US 10019				4	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip	p)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
(Instr. 3)		2. Transaction Date (Month/Day	Exe (/Year) Exe	A. Deemed xecution Date, if ny Month/Day/Year)		Code (Instr. 8)		4. Securities Acqu (A) or Disposed or (Instr. 3, 4 and 5)		d of (D)	Benefici Reported	unt of Securities ially Owned Following d Transaction(s)		6. Ownership Form:	Beneficial	
				(1)	violitii/Day/ i	cai)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	
Common \$0.001	Stock, par	value	08/31/201	15			D		3,500	D	\$ 2.9414	4 283,234	1		D	
			Tal				ies Acquir	ed, E	Disposed (of, or l	Benefici	ally Owned		ntrol numb	er.	
1. Title of Derivative Security (Instr. 3) 2. Conversion Date (Month/Date) Price of Derivative Security			ion 3A. Deeme Execution 3		Derivative Securities, puts, calls, was ate, if Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,	6. Date Exercisable and Expiration Da		tible s cisable on Dat	ecurities e 7. e Ar Ur Se		tle and unt of Derivative Security rities (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Owner Form of Deriva Securit Direct or Indi	Beneficia Ownershi y: (Instr. 4)
					Code	V	(A) (D)	Da Ex	te ercisable	Expira Date	ntion Ti	Amount or Number of Shares				
Repor	Reporting Owners															
Penauting Owner Name / Adduses					Relationships											
			Director	or 10% Owner Officer						Other						
Avgerino	s George															

Signatures

/s/ S. Halle Vakani, Attorney-in-Fact	09/02/2015
**Signature of Reporting Person	Date

Explanation of Responses:

C/O FORTRESS BIOTECH, INC.

NEW YORK, NY US 10019

3 COLUMBUS CIRCLE, 15TH FLOOR

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This transaction was executed in multiple trades at prices ranging from \$2.90 to \$2.98. The price reported in Column 4 is a weighted average price. The reporting person (1) hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the trades were effected.

SVP, Biologics Operations

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.